- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01616823
Fetal HIV Transmission Risk and Duration of Membrane Rupture
Duration of Rupture of Membranes and Risk of Fetal Transmission of HIV in Optimally Managed HIV Positive Mothers
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
In developed countries, HIV infection is now considered a chronic disease and thus the life expectancy of people infected with HIV is approaching that of the general population. Therefore many HIV positive women are choosing to pursue pregnancies. An important concern for antenatal and intrapartum management is decreasing the risk of vertical transmission. With the use of highly active antiretroviral therapy (HAART) and intrapartum IV zidovudine (ZDV) the risk of transmission is decreased significantly, however there is some debate surrounding optimal mode of delivery. Possible mechanisms leading to perinatal transmission include transfusion of the mother's blood to the fetus during labour contractions, infection after rupture of membranes and direct contact of the fetus with infected secretions or blood from the maternal genital tract.
When maternal viral load is detectable, The Society of Obstetricians and Gynaecologists of Canada (SOGC) and other governing bodies recommend that elective cesarean section be performed for delivery as there is a 12-fold increased risk of perinatal transmission. However, the evidence suggests that for women at very low risk of transmission, such as those with an undetectable viral load and on HAART, the benefit of transmission reduction provided by cesarean section may be negligible.
The question of length of time of rupture of membranes prior to delivery and transmission risk has been a source of controversy, especially in the context of women on suppressive therapy (HAART) with an undetectable viral load. Traditional thinking has stated that the length of time of rupture of membranes should not be longer than 4 hours, as the benefit of cesarean section is lost after this time. However, this thinking is based on data where maternal viral loads were not known and only intrapartum IV ZDV was used. Many practitioners believe that in women with undetectable viral loads, virally suppressed on HAART, the safest route of delivery is vaginal, irrespective of length of time of rupture of membranes.
This is a retrospective cohort study which plans to examine the mode of delivery and median length of time of rupture of membranes for HIV positive women in two downtown academic institutions in Toronto.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Ontario
-
Toronto, Ontario, Kanada, M5B 1W8
- St. Michael's Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- all HIV positive women from January 2000
Exclusion Criteria:
- women not on HAART and who were not receiving intrapartum intravenous zidovudine
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
---|
HIV Positive Women
HIV positive women in two downtown Toronto, Ontario academic-affiliated hospitals
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Mode of delivery
Tidsram: Ten years
|
In optimally managed HIV+ women with undetectable viral loads and on HAART, receiving intrapartum IV ZDV, the risk of vertical transmission of HIV is independent of the length of time of rupture of membranes (as a secondary measure)
|
Ten years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Median length of time of membrane rupture
Tidsram: Ten Years
|
In optimally managed HIV+ women with undetectable viral loads and on HAART, receiving intrapartum IV ZDV, the risk of vertical transmission of HIV is independent of the length of time of rupture of membranes (as a secondary measure)
|
Ten Years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunsystemets sjukdomar
- Sår och skador
- Långsamma virussjukdomar
- HIV-infektioner
- Brista
- Förvärvat immunbristsyndrom
- Immunologiska bristsyndrom
Andra studie-ID-nummer
- 10-232
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekryteringHIV | HIV-testning | HIV-koppling till vård | HIV-behandlingFörenta staterna
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationAvslutadPartners HIV-testning | Hiv-rådgivning för par | Par kommunikation | Hiv-incidensKamerun, Dominikanska republiken, Georgien, Indien
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement och andra samarbetspartnersOkändHIV | HIV-oinfekterade barn | Barn som utsätts för HIVKamerun
-
University of MinnesotaIndragenHIV-infektioner | HIV/AIDS | Hiv | AIDS | Aids/Hiv problem | AIDS och infektionerFörenta staterna
-
University of Maryland, BaltimoreIndragenHiv | Njurtransplantation | HIV-reservoar | CCR5Förenta staterna
-
Hospital Clinic of BarcelonaAvslutadIntegrashämmare, HIV; HIV PROTEAS HÄMMARSpanien
-
Erasmus Medical CenterHar inte rekryterat ännuHIV-infektioner | Hiv | HIV-1-infektion | HIV I-infektionNederländerna
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London och andra samarbetspartnersRekryteringHIV | HIV-testning | Koppling till vårdSydafrika
-
National Taiwan UniversityRekrytering
-
Helios SaludViiV HealthcareOkändHiv | HIV-1-infektionArgentina